Letter: Infliximab and adalimumab in the management of Crohn's disease - Are they really comparable?

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 5, 2012, Pages 498-499

  Lopez Sanroman, A ^a   Gisbert, J P ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ANUS DISEASE; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LETTER; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864666201     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05185.x     Document Type: Letter

References (7)

1. Zorzi F, Zuzzi S, Onali S, et al,. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther 2012; 35: 1397-407.
2. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
3. Singh JA, Wells GA, Christensen R, et al,. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
4. Rigby WF,. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 2007; 3: 227-33.
5. Billioud V, Sandborn WJ, Peyrin-Biroulet L,. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84.
6. Chaparro M, Panes J, García V, et al,. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011; 45: 113-8.
7. Chaparro M, Panés J, García V, et al,. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012; 18: 685-90.